Collegium Pharmaceutical (COLL) Cash from Financing Activities (2014 - 2026)

Collegium Pharmaceutical's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at -$21.3 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 15.43% year-over-year to -$21.3 million; the TTM figure through Mar 2026 stood at -$106.4 million (down 235.57% YoY), while the FY2025 annual figure was -$110.2 million, down 81.91% from the prior year.
• Cash from Financing Activities was -$21.3 million for Q1 2026 at Collegium Pharmaceutical, up from -$21.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $517.8 million in Q1 2022 to a low of -$114.2 million in Q2 2024.
• Historically, Cash from Financing Activities has averaged $6.1 million across 5 years, with a median of -$25.8 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities surged 4614.86% in 2022, then slumped 205.3% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$25.8 million in 2022, then sank by 162.66% to -$67.8 million in 2023, then soared by 39.14% to -$41.3 million in 2024, then soared by 47.14% to -$21.8 million in 2025, then grew by 2.2% to -$21.3 million in 2026.
• The last three Cash from Financing Activities figures came in at -$21.3 million (Q1 2026), -$21.8 million (Q4 2025), and -$14.8 million (Q3 2025), per Business Quant data.